CYTH Share Price Performance
US$0.72
-0.03 (-3.92%)
Price US$0.72
Share Pricen/a
Cyclo Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
CYTH Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Cyclo Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
- -0.86
- 91.24%
- -2,848.16%
- -90.4%
About CYTH
- Founded
- 1990
- Employees
- 8
- CEO
- WebsiteView website
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc.
